Interleukin 17A (IL17A) Antibody (FITC)

Background

IL17A is a pro-inflammatory cytokine produced primarily by T-helper 17 (Th17) cells and other immune cells in response to infection and tissue damage IL17A plays a central role in innate and adaptive immunity by stimulating the production of chemokines, cytokines, and antimicrobial peptides that recruit neutrophils and enhance host defense against bacterial and fungal infections Dysregulated IL17A production is associated with autoimmune diseases such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease, where it contributes to chronic inflammation and tissue damage IL17A also plays a role in cancer, where it can promote tumor growth and metastasis by inducing angiogenesis, immune suppression, and chronic inflammation IL17A-targeted therapies, including monoclonal antibodies such as secukinumab, have been developed to treat autoimmune and inflammatory conditions by neutralizing IL17A activity and reducing inflammation